NCT03538041 is a Phase 2 clinical trial of Parsaclisib in Autoimmune Hemolytic Anemia, sponsored by Incyte Corporation.

Who is sponsoring NCT03538041?

NCT03538041 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03538041?

Interventions in NCT03538041: Parsaclisib.

What condition does NCT03538041 study?

NCT03538041 studies Autoimmune Hemolytic Anemia.

Is NCT03538041 still recruiting?

NCT03538041 is currently completed. Last updated 11 July 2025.

Are results published for NCT03538041?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-11 · How we verify

NCT03538041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Completed Phase 2 Results posted Last updated 11 July 2025

What this trial tests

Phase 2 trial testing Parsaclisib in Autoimmune Hemolytic Anemia in 25 participants. Completed in 2 April 2024.

Timeline

21 November 2018

Primary endpoint
5 August 2021

2 April 2024

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	21 November 2018
Primary completion	5 August 2021
Estimated completion	2 April 2024
Sites	12 locations across Austria, France, United States, Italy

Drugs / interventions tested

Parsaclisib — full drug profile →

Conditions studied

Autoimmune Hemolytic Anemia — all drugs for Autoimmune Hemolytic Anemia →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Autoimmune Hemolytic Anemia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants Attaining a Complete Response at Any Visit From Week 6 to Week 12 Primary · Week 6 to Week 12

A complete response was defined as hemoglobin \>12 grams per deciliter (g/dL) not attributed to a transfusion effect and the normalization of hemolytic markers. No transfusion effect was defined as \> 1 week since the last transfusion.

Group	Value	95% CI
Parsaclisib 1 mg QD	20.0
Parsaclisib 2.5 mg QD	40.0

Percentage of Participants Attaining a Partial Response at Any Visit From Week 6 to Week 12 Primary · Week 6 to Week 12

A partial response was defined as hemoglobin 10-12 g/dL or at least a 2 g/dL increase from Baseline not attributed to a transfusion effect and the normalization of hemolytic markers. No transfusion effect was defined as \> 1 week since the last transfusion.

Group	Value	95% CI
Parsaclisib 1 mg QD	60.0
Parsaclisib 2.5 mg QD	66.7

Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Primary · up to 1638 days

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy, or required changes in the study drug. Anemia and transfusions should not have been reported as AEs unless they represented a clinically meaningful decrease from Baseline in hemoglobin. A

Group	Value	95% CI
Parsaclisib 1 mg QD	10
Parsaclisib 2.5 mg QD	15

Percentage of Participants Attaining a Complete Response During Post-Baseline Visits Secondary · up to 1638 days

A complete response was defined as hemoglobin \>12 g/dL) not attributed to a transfusion effect and the normalization of hemolytic markers. No transfusion effect was defined as \> 1 week since the last transfusion.

Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	6.7

Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	10.0
Parsaclisib 2.5 mg QD	6.7

Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	21.4

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	28.6

Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	23.1

Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	23.1

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	42.9

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Percentage of Participants Attaining a Partial Response During Post-Baseline Visits Secondary · up to 1638 days

Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	50.0
Parsaclisib 2.5 mg QD	53.3

Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	50.0
Parsaclisib 2.5 mg QD	66.7

Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	44.4
Parsaclisib 2.5 mg QD	64.3

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	44.4
Parsaclisib 2.5 mg QD	50.0

Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	55.6
Parsaclisib 2.5 mg QD	61.5

Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	55.6
Parsaclisib 2.5 mg QD	61.5

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	55.6
Parsaclisib 2.5 mg QD	64.3

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	50.0
Parsaclisib 2.5 mg QD	0.0

Percentage of Participants Attaining a ≥ 2 g/dL Increase in Hemoglobin From Baseline Secondary · up to 1638 days

Hemoglobin levels were assessed throughout the study.

Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	26.7

Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	10.0
Parsaclisib 2.5 mg QD	46.7

Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	42.9

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	35.7

Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	33.3
Parsaclisib 2.5 mg QD	38.5

Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	46.2

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	33.3
Parsaclisib 2.5 mg QD	50.0

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Change From Baseline in Hemoglobin Secondary · Baseline; up to 1638 days

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Baseline

Group	Value	95% CI
Parsaclisib 1 mg QD	9.1	± 0.80
Parsaclisib 2.5 mg QD	8.7	± 0.85

Change from Baseline at Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.9	± 0.84
Parsaclisib 2.5 mg QD	1.2	± 1.30

Change from Baseline at Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	0.6	± 0.96
Parsaclisib 2.5 mg QD	1.5	± 1.75

Change from Baseline at Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	0.9	± 1.06
Parsaclisib 2.5 mg QD	1.6	± 1.79

Change from Baseline at Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	1.2	± 0.80
Parsaclisib 2.5 mg QD	1.7	± 1.96

Change from Baseline at Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	1.2	± 1.14
Parsaclisib 2.5 mg QD	2.0	± 2.07

Change from Baseline at Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	1.3	± 1.14
Parsaclisib 2.5 mg QD	2.1	± 2.22

Change from Baseline at Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	1.3	± 1.46
Parsaclisib 2.5 mg QD	2.5	± 2.67

Percentage Change From Baseline in Hemoglobin Secondary · Baseline; up to 1638 days

Percentage change from Baseline was calculated as: (\[post-Baseline value minus the Baseline value\] / Baseline value) x 100.

Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	10.1	± 9.23
Parsaclisib 2.5 mg QD	14.4	± 16.31

Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	6.0	± 10.26
Parsaclisib 2.5 mg QD	18.5	± 20.71

Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	9.9	± 10.83
Parsaclisib 2.5 mg QD	19.2	± 20.65

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	13.3	± 8.35
Parsaclisib 2.5 mg QD	19.5	± 22.35

Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	12.7	± 12.16
Parsaclisib 2.5 mg QD	23.4	± 24.57

Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	14.1	± 11.54
Parsaclisib 2.5 mg QD	25.1	± 26.30

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	13.9	± 15.72
Parsaclisib 2.5 mg QD	30.2	± 33.95

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0	± 12.26
Parsaclisib 2.5 mg QD	-4.1	± 7.92

Percentage of Participants Requiring Transfusions Secondary · Baseline; up to 1638 days

A participant was defined to have required a transfusion if his or her last transfusion was within 7 days of the visit date.

Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	6.7

Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	22.2
Parsaclisib 2.5 mg QD	0.0

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	15.4

Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	7.7

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Percentage of Participants Who Achieved Normalization of Hemoglobin, Haptoglobin, Lactate Dehydrogenase (LDH), Reticulocyte Count, Total Bilirubin, Direct Bilirubin, and Indirect Bilirubin Secondary · up to 1638 days

Normalization was determined by the Investigator based on normal ranges for the clinical reference laboratory.

Hemoglobin, Week 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	6.7

Hemoglobin, Week 2

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	6.7

Hemoglobin, Week 4

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	14.3

Hemoglobin, Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	21.4

Hemoglobin, Week 8

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	15.4

Hemoglobin, Week 10

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	15.4

Hemoglobin, Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	11.1
Parsaclisib 2.5 mg QD	35.7

Hemoglobin, Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Percentage of Participants Requiring a Prednisone Dose Change (Increase or Decrease) Secondary · up to 1638 days

Prednisone use was monitored throughout the study.

Week 1, increased

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	6.7

Week 1, decreased

Group	Value	95% CI
Parsaclisib 1 mg QD	20.0
Parsaclisib 2.5 mg QD	6.7

Week 2, increased

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Week 2, decreased

Group	Value	95% CI
Parsaclisib 1 mg QD	20.0
Parsaclisib 2.5 mg QD	13.3

Week 4, increased

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Week 4, decreased

Group	Value	95% CI
Parsaclisib 1 mg QD	10.0
Parsaclisib 2.5 mg QD	6.7

Week 6, increased

Group	Value	95% CI
Parsaclisib 1 mg QD	0.0
Parsaclisib 2.5 mg QD	0.0

Week 6, decreased

Group	Value	95% CI
Parsaclisib 1 mg QD	10.0
Parsaclisib 2.5 mg QD	6.7

Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale Scores Secondary · Baseline; up to 1638 days

The FACIT-F subscale is a 13-item instrument designed to assess fatigue/tiredness and its impact on daily activities and functioning in a number of chronic diseases. Participants were asked to respond to 13 statements that people with the illness have said are important on the following scale: 0, not at all; 1, a little bit; 2, somewhat; 3, quite a bit; 4, very much. Participants were asked to indicate the response as it applied to the last 7 days. The total fatigue subscale score ranges from 0 to 52; a higher score indicates more severe impact on daily activities and functioning.

Baseline

Group	Value	95% CI
Parsaclisib 1 mg QD	32.6	± 12.80
Parsaclisib 2.5 mg QD	30.1	± 13.88

Week 6

Group	Value	95% CI
Parsaclisib 1 mg QD	6.7	± 12.44
Parsaclisib 2.5 mg QD	8.2	± 9.28

Week 12

Group	Value	95% CI
Parsaclisib 1 mg QD	6.2	± 16.08
Parsaclisib 2.5 mg QD	5.4	± 15.49

Follow-up Month 1

Group	Value	95% CI
Parsaclisib 1 mg QD	2.0	± 2.83
Parsaclisib 2.5 mg QD	2.3	± 10.69

Follow-up Month 2

Group	Value	95% CI
Parsaclisib 1 mg QD	1.5	± 7.78
Parsaclisib 2.5 mg QD	7.0	± 15.56

Follow-up Month 3

Group	Value	95% CI
Parsaclisib 1 mg QD	-2.0	± 21.21
Parsaclisib 2.5 mg QD	13.0	± 14.14

Adverse events — posted to ClinicalTrials.gov

Time frame: up to a maximum of 1638 days. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Parsaclisib 1 mg QD

Serious: 6/10 (60%)

Deaths: 0/10

Parsaclisib 2.5 mg QD

Serious: 5/15 (33%)

Deaths: 1/15

Serious adverse events (28 terms)

Reaction	System	Parsaclisib 1 mg QD	Parsaclisib 2.5 mg QD
Acute respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—
COVID-19 pneumonia	Infections and infestations	—	—
Amoebic dysentery	Infections and infestations	—	—
Aortic thrombosis	Vascular disorders	—	—
Atypical mycobacterial infection	Infections and infestations	—	—
Autoimmune haemolytic anaemia	Blood and lymphatic system disorders	—	—
Bacterial sepsis	Infections and infestations	—	—
COVID-19	Infections and infestations	—	—
Campylobacter colitis	Infections and infestations	—	—
Cytomegalovirus infection reactivation	Infections and infestations	—	—
Diabetes insipidus	Endocrine disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Enterococcal infection	Infections and infestations	—	—
Fall	Injury, poisoning and procedural complications	—	—
Femur fracture	Injury, poisoning and procedural complications	—	—
Haemolytic anaemia	Blood and lymphatic system disorders	—	—
Hypernatraemia	Metabolism and nutrition disorders	—	—
Interstitial lung disease	Respiratory, thoracic and mediastinal disorders	—	—
Invasive ductal breast carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Pneumonia	Infections and infestations	—	—
Pseudomonas infection	Infections and infestations	—	—
Psoriasis	Skin and subcutaneous tissue disorders	—	—
Pulmonary fibrosis	Respiratory, thoracic and mediastinal disorders	—	—
Pulmonary haemorrhage	Respiratory, thoracic and mediastinal disorders	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—

Other adverse events (123 terms — click to expand)

Reaction	System	Parsaclisib 1 mg QD	Parsaclisib 2.5 mg QD
Pyrexia	General disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Oedema peripheral	General disorders	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
COVID-19	Infections and infestations	—	—
Headache	Nervous system disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—
Pneumonia	Infections and infestations	—	—
Rash	Skin and subcutaneous tissue disorders	—	—
Autoimmune haemolytic anaemia	Blood and lymphatic system disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Dizziness	Nervous system disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Hyperuricaemia	Metabolism and nutrition disorders	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—
Neutropenia	Blood and lymphatic system disorders	—	—
Psoriasis	Skin and subcutaneous tissue disorders	—	—
Rash pruritic	Skin and subcutaneous tissue disorders	—	—
SARS-CoV-2 test positive	Investigations	—	—
Vomiting	Gastrointestinal disorders	—	—
Abdominal distension	Gastrointestinal disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Agitation	Psychiatric disorders	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Angina pectoris	Cardiac disorders	—	—
Arrhythmia	Cardiac disorders	—	—
Asthenia	General disorders	—	—
Bacteraemia	Infections and infestations	—	—
Blister	Skin and subcutaneous tissue disorders	—	—
Blood bilirubin increased	Investigations	—	—
Blood creatinine increased	Investigations	—	—
Blood potassium decreased	Investigations	—	—
Bone pain	Musculoskeletal and connective tissue disorders	—	—
Breath sounds abnormal	Investigations	—	—
Cardiac discomfort	Cardiac disorders	—	—
Chest discomfort	General disorders	—	—
Chromaturia	Renal and urinary disorders	—	—
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	—	—

Most-reported serious reactions: Acute respiratory failure, COVID-19 pneumonia, Amoebic dysentery, Aortic thrombosis, Atypical mycobacterial infection, Autoimmune haemolytic anaemia, Bacterial sepsis, COVID-19.

Data from ClinicalTrials.gov NCT03538041 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. · · 2020 · cited 75× · PMID 33261023 · DOI 10.3390/jcm9123859
Autoimmune hemolytic anemia: current knowledge and perspectives.
Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, et al · · 2020 · cited 72× · PMID 33292368 · DOI 10.1186/s12979-020-00208-7
Infectious Complications in Autoimmune Hemolytic Anemia.
Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. · · 2021 · cited 23× · PMID 33466516 · DOI 10.3390/jcm10010164
Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy.
Cui R, Luo Z, Zhang X, Yu X, et al · · 2025 · cited 10× · PMID 40266213 · DOI 10.3390/vaccines13030292
Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.
Barcellini W, Fattizzo B. · · 2024 · cited 10× · PMID 39371250 · DOI 10.1159/000540475
Rise of the planet of rare anemias: An update on emerging treatment strategies.
Fattizzo B, Motta I. · · 2022 · cited 8× · PMID 36698833 · DOI 10.3389/fmed.2022.1097426
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
Barcellini W, Pane F, Patriarca A, Murakhovskaya I, et al · · 2024 · cited 7× · PMID 39435908 · DOI 10.1002/ajh.27493
The EHA Research Roadmap: Anemias.
Iolascon A, Rivella S, Anagnou NP, Camaschella C, et al · · 2021 · cited 7× · PMID 34522846 · DOI 10.1097/hs9.0000000000000607

Verify or expand the search:

Other trials of Parsaclisib

Trials testing the same drug.

NCT07149818 — A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolyti · not yet recruiting
NCT05083208 — PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma · Phase 1 · terminated
NCT04774068 — Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas · Phase 1 · completed
NCT04509700 — Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies o · Phase 2 · active not recruiting
NCT04323956 — Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma · Phase 1 · active not recruiting

Other recruiting trials for Autoimmune Hemolytic Anemia

Currently open trials in the same condition.

NCT07441525 — UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases · EARLY_PHASE1 · recruiting
NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
NCT06921980 — Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia · recruiting
NCT06733610 — CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. · Phase 1 · recruiting
NCT06888960 — Safety Study of CC312 in Autoimmune Disease Patients · EARLY_PHASE1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03538041 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 11 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03538041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03538041

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (28 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Parsaclisib

Other recruiting trials for Autoimmune Hemolytic Anemia

Other Incyte Corporation trials

Verify against primary sources